一年一度的全球泌尿外科界盛会——美国泌尿外科协会（AUA）年会将于当地时间4月28日至5月1日在美国芝加哥盛大召开。作为世界上最大、最具影响力的泌尿外科学术会议，AUA年会汇聚了世界各地泌尿领域的开拓性研究、新指南及泌尿医学最新进展。医脉通对泌尿肿瘤领域的部分重磅研究进展进行了梳理，一起来看看吧！

前列腺癌领域

摘要号：LBA02-03

标题：FIRST RESULTS FROM SUNRISE-1 IN PATIENTS WITH BCGUNRESPONSIVE HIGH-RISK NONeMUSCLE-INVASIVE BLADDERCANCER RECEIVING TAR-200 IN COMBINATION WITHCETRELIMAB, TAR-200, OR CETRELIMAB ALONE

第一作者：Siamak Daneshmand

摘要号：LBA02-09

标题：EMBARK: A PHASE 3 RANDOMIZED STUDY OF ENZALUTAMIDE OR PLACEBO PLUS LEUPROLIDE ACETATE AND ENZALUTAMIDE MONOTHERAPY IN HIGH-RISK BIOCHEMICALLY RECURRENT PROSTATE CANCER

第一作者：Neal D. Shore

摘要号：LBA02-11

标题：UPDATED PROGRESSION-FREE SURVIVAL FROM PRESTO: A PHASE 3 RANDOMIZED STUDY OF ANDROGEN ANNIHILATION FOR HIGH-RISK BIOCHEMICALLY RELAPSED PROSTATE CANCER (AFT-19)

第一作者：Rahul Aggarwal

摘要号：MP11-07

标题：RADIOLIGAND THERAPY WITH 177LU-PSMA-I&T IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: ONCOLOGICAL OUTCOMES AND TOXICITY PROFILE

第一作者：Mehmet Onur Demirkol

摘要号：MP11-13

标题：CLINICAL FRACTURE INCIDENCE IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) AND RISK-REDUCTION FOLLOWING ADDITION OF ZOLEDRONIC ACID TO ANDROGEN DEPRIVATION THERAPY (ADT) WITH OR WITHOUT DOCETAXEL (DOC): LONG-TERM RESULTS FROM 2 PHASE 3 TRIALS FROM THE STAMPEDE PLATFORM PROTOCOL

第一作者：Craig Jones

摘要号：MP11-14

标题：TREATMENT DURATION AND LONG-TERM SAFETY AND TOLERABILITY WITH DAROLUTAMIDE IN NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC): ARAMIS ROLLOVER STUDY

第一作者：Neal D. Shore

摘要号：MP11-15

标题：THE EFFECT OF A REDUCED DOSE OF APALUTAMIDE ON SKIN-RELATED ADVERSE EVENTS IN ADVANCED PROSTATE CANCER: A MULTICENTER RETROSPECTIVE STUDY

第一作者：Kyo Togashi

摘要号：MP11-16

标题：PROSTATE-SPECIFIC ANTIGEN ANALYSES IN PROPEL: ABIRATERONE AND OLAPARIB VERSUS ABIRATERONE AND PLACEBO AS FIRST-LINE THERAPY FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

第一作者：Fred Saad

摘要号：MP29-01

标题：RAPID, DURABLE, AND DEEP PROSTATE-SPECIFIC ANTIGEN RESPONSE FOLLOWING ADDITION OF DAROLUTAMIDE TO ANDROGEN-DEPRIVATION THERAPY AND DOCETAXEL IN ARASENS

第一作者：Fred Saad

摘要号：MP29-02

标题：EFFICACY AND SAFETY OF DAROLUTAMIDE IN COMBINATION WITH ANDROGEN-DEPRIVATION THERAPY AND DOCETAXEL IN THE NORTH AMERICAN POPULATION FROM ARASENS

第一作者：Neal D. Shore

摘要号：MP29-13

标题：REAL-WORLD STUDY ON DAROLUTAMIDE, ENZALUTAMIDE, AND APALUTAMIDE FOR NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS USING A UROLOGY NETWORK IN THE UNITED STATES (DEAR STUDY)

第一作者：Neal D. Shore

摘要号：MP29-14

标题：PROSTATE-SPECIFIC ANTIGEN RESPONSE AND TIME-TO-CASTRATION RESISTANCE AMONG PATIENTS WITH METASTATIC CASTRATION SENSITIVE PROSTATE CANCER INITIATED ON APALUTAMIDE, ENZALUTAMIDE, OR ABIRATERONE ACETATE

第一作者：Benjamin Lowentritt

摘要号：PD16-03

标题：PROGNOSTIC VALUE OF PROSTATE-SPECIFIC ANTIGEN KINETICS DURING TREATMENT OF ADVANCED PROSTATE CANCER WITH ABIRATERONE AND ENZALUTAMIDE: MULTICENTER ANALYSIS

第一作者：Byeong Jin Kang

肾癌领域

摘要号：LBA03-01

标题：89ZR-DFO-GIRENTUXIMAB FOR PET/CT IMAGING OFINDETERMINATE RENAL MASSESeRESULTS FROM PHASE 3ZIRCON STUDY

第一作者：Brian Shuch

摘要号：MP28-06

标题： CLINICAL IMPLICATIONS AND PREDICTIVE FACTORS OF PRIMARY RESISTANCE TO NIVOLUMAB PLUS IPILIMUMAB THERAPY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA

第一作者：Kazuyuki Numakura

摘要号：MP28-07

标题：THE ASSOCIATION OF SOLUBLE PD-L1 AND TREATMENT RESPONSE TO NIVOLUMAB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA

第一作者：Naoto Wakita

摘要号：PD24-06

标题：ASSESSMENT OF SURGICAL COMPLICATIONS IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA (MCCRCC) RECEIVING PERIOPERATIVE CABOZANTINIB AND NIVOLUMAB ON CYTO-KIK CLINICAL TRIAL

第一作者：Karie Runcie

摘要号：PD24-08

标题：SEQUENTIAL USAGE OF MTOR INHIBITOR FOLLOWED BY IMMUNOTHERAPIES FOR CABOZANTINIB-RESISTANT METASTATIC CLEAR CELL RENAL CELL CARCINOMAS

第一作者：Jee Soo Park

摘要号：PD24-09

标题：PHASE II, MULTI-CENTER STUDY OF SINTILIMAB IN COMBINATION WITH AXITINIB IN PATIENTS WITH ADVANCED FUMARATE HYDRATASE-DEFICIENT RENAL CELL CARCINOMA

第一作者： Xingming Zhang

尿路上皮癌领域

摘要号：LBA02-08

标题：RESULTS FROM THE EXTENDED FOLLOW-UP IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER IN THE CHeckMATE 274 TRIAL

第一作者：Matthew Milowsk

摘要号：LBA03-08

标题：PEMBROLIZUMAB (PEMBRO) FOR PATIENTS (PTS) WITH HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER (HR NMIBC) UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN (BCG): EFFICACY AND EVALUATION OF SUBSEQUENT CYSTECTOMY FROM COHORT B OF THE PHASE 2 KEYNOTE-057 STUDY

第一作者：Eric Singer

摘要号：PD13-08

标题：CORE1: PHASE 2 SINGLE ARM STUDY OF CG0070 COMBINED WITH PEMBROLIZUMAB IN PATIENTS WITH NON MUSCLE INVASIVE BLADDER CANCER UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN (BCG)

第一作者：Roger Li

摘要号：MP63-05

标题：OUTCOMES IN PATIENTS (PTS) WITH BACILLUS CALMETTE-GUERIN (BCG)-UNRESPONSIVE HIGH-RISK (HR) NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC) WHO UNDERWENT RADICAL CYSTECTOMY (RC) FOLLOWING PEMBROLIZUMAB (PEMBRO) TREATMENT IN KEYNOTE-057 COHORT A

第一作者：Girish S. Kulkarni

摘要号：PD09-10

标题：AVELUMAB FIRST-LINE (1L) MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA (UC): LONG-TERM OUTCOMES FROM JAVELIN BLADDER 100 IN SUBGROUPS DEFINED BY RESPONSE TO 1L CHEMOTHERAPY

第一作者： Begona Valderrama

摘要号：PD09-11

标题：THE IMMUNE-RELATED ADVERSE EVENTS PARADOX IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER PATIENTS RECEIVING ATEZOLIZUMAB: ANALYSIS OF INDIVIDUAL PARTICIPANT DATA FROM IMVIGOR210 AND IMVIGOR211

第一作者：Daniele Robesti

摘要号：MP32-01

标题：ONCOLOGICAL OUTCOMES IN PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA AFTER DISCONTINUING PEMBROLIZUMAB AS A SECOND-LINE TREATMENT: A RETROSPECTIVE MULTICENTER REAL-WORLD COHORT STUDY

第一作者：Toyohiro Yamada

摘要号：PD36-08

标题：PERIOPERATIVE OUTCOMES OF RADICAL CYSTECTOMY FOLLOWING NEOADJUVANT GEMCITABINE, CISPLATIN AND ATEZOLIZUMAB

第一作者：Si Hyun Kim

摘要号：PD44-06

标题：CHEMOTHERAPY VS IMMUNOTHERAPY AS NEOADJUVANT THERAPIES IN CISPLATIN-ELIGIBLE PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR MUSCLE INVASIVE BLADDER CANCER

第一作者：Luigi Nocera

摘要号：MP56-09

标题：NEOADJUVANT PEMBROLIZUMAB SHOWS PROMISE AS EFFECTIVE SYSTEMIC THERAPY PRIOR TO RADICAL CYSTECTOMY FOR CISPLATIN-INELIGIBLE MUSCLE INVASIVE BLADDER CANCER

第一作者：Kyle Rose

备注：排名不分先后，按照摘要号进行

如有遗漏，请给我们留言~